How to incentivize higher quality and lower cost in U.S. medical care
U.S. health care costs are high – over $3 trillion annually and about 18 percent of our GDP. Estimates suggest that our costs are rising. Concomitantly, we are entering an era of extreme biomedical promise, where research breakthroughs are translating into unprecedented clinical benefit.
Luxturna from Spark therapeutics, for example, remarkably restores vision loss in patients with a specific eye disease. With amazing innovations, …
How to incentivize higher quality and lower cost in U.S. medical care
